a. MK-I
b. BFU-Meg
c. CFU-Meg
d. LD-CFU-Meg
d. LD-CFU-Meg
a. IL-3
b. IL-6
c. IL-11
d. Thrombopoietin
d. Thrombopoietin
a. Glycocalyx
b. Dense granules
c. Dense tubular system
d. Surface connected canalicular system
c. Dense tubular system
a. GP Ib/IX/V
b. GP IIb/IIIa
c. GP Ia/IIa
d. P2Y1
b. GP IIb/IIIa
a. Phosphatidylethanolamine
b. Phosphatidylinositol
c. Phosphatidylcholine
d. Phosphatidylserine
d. Phosphatidylserine
a. Thromboxane A2
b. Arachidonic acid
c. Cyclooxygenase
d. Prostacyclin
d. Prostacyclin
a. Serotonin
b. Fibrinogen
c. Platelet factor 4
d. Platelet-derived growth factor
a. Serotonin
a. VWF
b. Factor VIII
c. Fibrinogen
d. P-selectin
a. VWF
a. Impaired platelet production in disease
states
b. Abnormal organelles associated with
diseases such as leukemia
c. Increased platelet production in
response to need
d. Inadequate rates of membrane
cholesterol exchange with the plasma
c. Increased platelet production in
response to need
a. Occur primarily in the deep veins of the
leg
b. Are characteristic of the secondary
hemostatic process
c. Are largely composed of platelets and
von Willebrand factor
d. Form normally in response to vascular
injury and are completely harmless
c. Are largely composed of platelets and
von Willebrand factor
a. The dense tubule system
b. The surface connected canalicular
system
c. The glycocalyx
d. Microtubules
b. The surface connected canalicular
system
a. Are stored in platelet dense granules
b. Inhibit blood clotting
c. Bud off of platelets after their exposure
to strong agonists
d. Exhibit no biologic activity
c. Bud off of platelets after their exposure
to strong agonists
a. 0.25
b. 2.5
c. 5
d. 10
b. 2.5
a. 0.8
b. 8
c. 16
d. 19
c. 16
a. Methemoglobin
b. Azide methemoglobin
c. Cyanmethemoglobin
d. Myoglobin
c. Cyanmethemoglobin
a. Increased lipids
b. Elevated WBC count
c. Lyse-resistant RBCs
d. Fetal hemoglobin
d. Fetal hemoglobin
a. 21% to 24%
b. 23.7% to 24.3%
c. 24% to 27%
d. 21% to 27%
d. 21% to 27%
a. 30 18
b. 60 30
c. 65 33
d. 85 35
b. 60 30
a. Inflammation
b. Response to infection
c. Erythropoietic activity of the bone
marrow
d. Ability of red blood cells to form rouleaux
c. Erythropoietic activity of the bone
marrow
a. Observed reticulocyte count
b. Corrected reticulocyte count
c. RPI
d. ARC
c. RPI
a. 2
b. 3
c. 4
d. 5
a. 2
a. Microcytosis
b. Polycythemia
c. Decreased globulins
d. Inflammation
d. Inflammation
a. CELL-DYN Sapphire
b. UniCel DxH 800
c. ADVIA 2120i
d. Sysmex XN-series
d. Sysmex XN-series
a. CELL-DYN Sapphire
b. UniCel DxH 800
c. ADVIA 2120i
d. XN-series
a. CELL-DYN Sapphire